The abstract is read at the publisher; the summary is JClub's.
An integrative, liver gene-expression–anchored multi-omics pipeline prioritized 39 candidate regulators of metabolic dysfunction-associated steatotic liver disease, with MLIP validated in lipid overload hepatocytes.
- Why it matters: MASLD is common and can progress to advanced fibrosis, yet therapeutic options are limited, creating a need to pinpoint regulatory genes and mechanisms across disease stages.
- What they did: The pipeline combined differential meta-analysis across three MASLD stages, transcriptome-wide Mendelian randomization and TWAS, plus gene scoring using expression–phenotype correlations, PWAS, and external GWAS Catalog/ExPheWAS data. It also used snRNA-seq to map prioritized gene expression across liver cell types and stages, and then experimentally tested MLIP in a lipid overload hepatocyte model.
- The result: Stage- and cell-type-specific expression patterns emerged for the 39 regulators, and MLIP was confirmed as a functional modulator of hepatocellular lipid accumulation, supporting future mechanistic and therapeutic work.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.